SCHEMBL1637173

SCHEMBL1637173

C#Cc1cccc(C(=O)Oc2ccccc2)c1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.51
TDP1 Q9NUW8 3/20 0.51
NSD2 O96028 1/20 0.50
MAPK1 P28482 1/20 0.50
FABP7 O15540 1/20 0.49
FABP5 Q01469 1/20 0.49
ALDH1A1 P00352 4/20 0.48
KMT2A Q03164 6/20 0.47
MEN1 O00255 2/20 0.47
PARP10 Q53GL7 1/20 0.46
ALOX5 P09917 1/20 0.45
SERPINE1 P05121 1/20 0.44
ESR1 P03372 2/20 0.44
ESR2 Q92731 2/20 0.44
GALR1 P47211 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
PKM P14618 1/20 0.44
HAO1 Q9UJM8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14501374 0.90 FABP7 (0.56) MAPTTDP1NSD2FABP7FABP5
SCHEMBL13132602 0.86 FABP7 (0.43) MAPTTDP1MAPK1FABP7FABP5
SCHEMBL4354653 0.85 MAPT (0.52) MAPTTDP1NSD2MAPK1ALDH1A1
SCHEMBL13692722 0.85 MAPT (0.50) MAPTTDP1MAPK1FABP7FABP5
SCHEMBL8394217 0.84 PRSS1 (0.54) MAPTTDP1NSD2MAPK1ALDH1A1
SCHEMBL10411916 0.84 MAPT (0.51) MAPTTDP1NSD2MAPK1ALDH1A1
SCHEMBL3849164 0.84 MAPT (0.51) MAPTTDP1NSD2MAPK1ALDH1A1
SCHEMBL14501378 0.83 FABP7 (0.51) MAPTTDP1NSD2FABP7FABP5
SCHEMBL69684 0.82 NSD2 (0.63) MAPTTDP1NSD2MAPK1ALDH1A1
SCHEMBL165917 0.81 PARP10 (0.59) MAPTTDP1NSD2ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2042506-B1 SUBSTITUTED PHENYLETHYNYL GOLD-NITROGENATED HETEROCYCLIC CARBENE COMPLEX UBE INDUSTRIES (JP) 2012-12-19 EP disclosed
CN-101454329-B Substituted phenylethynyl gold-nitrogenated heterocyclic carbene complex UBE INDUSTRIES, LTD. (JP) 2012-02-22 CN disclosed
US-7932398-B2 Substituted phenylethynylgold-nitrogen-containing heterocyclic carbene complex UBE INDUSTRIES, LTD. (JP) 2011-04-26 US disclosed
US-20090234130-A1 SUBSTITUTED PHENYLETHYNYLGOLD-NITROGEN-CONTAINING HETEROCYCLIC CARBENE COMPLEX UBE INDUSTRIES, LTD. (JP) 2009-09-17 US disclosed
EP-1457511-B1 CROSSLINKABLE AROMATIC RESINS HAVING PROTONIC ACID GROUPS AND ION CONDUCTIVE POLYMER MEMBRANES BINDERS AND FUEL CELLS MADE BY USING THE SAME MITSUI CHEMICALS INC (JP) 2009-07-15 EP disclosed
CN-101454329-A Substituted phenylethynyl gold-nitrogenated heterocyclic carbene complex UBE INDUSTRIES (JP) 2009-06-10 CN disclosed
EP-2042506-A1 SUBSTITUTED PHENYLETHYNYL GOLD-NITROGENATED HETEROCYCLIC CARBENE COMPLEX Ube Industries, Ltd. (JP) 2009-04-01 EP disclosed
CN-100462389-C Crosslinkable aromatic resin having protonic acid group, and ion conductive polymer membrane, binder and fuel cell using the resin MITSUI CHEMICALS INC (JP) 2009-02-18 CN disclosed
US-7345135-B2 Crosslinkable aromatic resin having protonic acid group, and ion conductive polymer membrane, binder and fuel cell using the resin MITSUI CHEMICALS, INC. (JP) 2008-03-18 US disclosed
CN-1630676-A Crosslinkable aromatic resin having protonic acid group, and ion conductive polymer membrane, binder and fuel cell using the resin MITSUI CHEMICALS INC (JP) 2005-06-22 CN disclosed
US-20040191602-A1 Crosslinkable aromatic resin having protonic acid group, and ion conductive polymer membrane, binder and fuel cell using the resin MITSUI CHEMICALS, INC. (JP) 2004-09-30 US disclosed
EP-1457511-A1 CROSSLINKABLE AROMATIC RESINS HAVING PROTONIC ACID GROUPS AND ION CONDUCTIVE POLYMER MEMBRANES BINDERS AND FUEL CELLS MADE BY USING THE SAME Mitsui Chemicals, Inc. (JP) 2004-09-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090234130-A1 SUBSTITUTED PHENYLETHYNYLGOLD-NITROGEN-CONTAINING HETEROCYCLIC CARBENE COMPLEX CCRL2, CCNL2, ATXN2L MAPT 4610/4885TDP1 4727/4885NSD2 3423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.